MyFinsight
Home
Blog
About
Net income
$229,913K
(-18.83%↓ Y/Y)
Amortization of intangible
assets
$29,512K
(-16.92%↓ Y/Y)
Inventories
-$18,332K
(-221.20%↓ Y/Y)
Share-based compensation
$17,698K
(-22.49%↓ Y/Y)
Depreciation and
amortization
$4,455K
(-17.91%↓ Y/Y)
Amortization of debt discount
$2,254K
(-39.05%↓ Y/Y)
Accounts receivable, net
and contract assets
-$2,162K
(-127.42%↓ Y/Y)
Deferred income taxes
-$907K
(-109.11%↓ Y/Y)
Lease payments
recognized
-$215K
(57.84%↑ Y/Y)
Loss on disposal of
equipment
-$76K
Realized loss on
marketable securities
-$28K
(-7.69%↓ Y/Y)
Net cash provided by
operating activities
$240,891K
(-5.14%↓ Y/Y)
Canceled cashflow
$64,661K
Net increase
(decrease) in cash and cash...
-$148,023K
(-174.17%↓ Y/Y)
Canceled cashflow
$240,891K
Proceeds from issuance of
common stock under...
$4,865K
(304.74%↑ Y/Y)
Proceeds from sales and
maturities of marketable...
$53,269K
(-77.74%↓ Y/Y)
Prepaid expenses and
other assets
$41,148K
(0.21%↑ Y/Y)
Accounts payable and
accrued expenses
-$22,911K
(-11.90%↓ Y/Y)
Accretion of premium on
marketable securities, net
$602K
(-78.83%↓ Y/Y)
Net cash used in
financing activities
-$326,251K
(-7.93%↓ Y/Y)
Canceled cashflow
$4,865K
Net cash used in
investing activities
-$62,663K
(-1012.23%↓ Y/Y)
Canceled cashflow
$53,269K
Repurchase of common stock
$332,729K
(9.63%↑ Y/Y)
Purchases of marketable
securities
$111,759K
(-53.89%↓ Y/Y)
Purchases of property and
equipment
$4,173K
(66.06%↑ Y/Y)
Back
Back
Cash Flow
HALOZYME THERAPEUTICS, INC. (HALO)
HALOZYME THERAPEUTICS, INC. (HALO)
source: myfinsight.com